Avid Bioservices Inc (CDMO)

[hutschi]

PEREGRINE PHARMACEUTICALS INC FILES -- 8-K
EDG
09/11/2017 9:37 PM

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20170911:EDG_0001683168-17-002334





Item 9.01 Financial Statements and Exhibits.


(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

Exhibit


Number


99.1 Press Release issued September 11, 2017.

Item 8.01 Other Events.


On September 11, 2017, Peregrine Pharmaceuticals, Inc. (the "Company") issued a press release announcing the appointment of Roger J. Lias, Ph.D. as the new president of Avid Bioservices, Inc., the Company’s wholly-owned contract development and manufacturing organization subsidiary, and his appointment to the Company’s Board of Directors. A copy of the press release is attached hereto as Exhibit 99.1.


Important Additional Information


Peregrine intends to file a proxy statement with the Securities and Exchange Commission (SEC) in connection with the solicitation of proxies for Peregrine’s 2017 Annual Meeting (Proxy Statement) with an associated WHITE proxy card. Peregrine, its directors and certain of its executive officers will be participants in the solicitation of proxies from stockholders in respect of the 2017 Annual Meeting. Information regarding the names of Peregrine’s directors and executive officers and their respective interests in Peregrine by security holdings or otherwise is set forth in the Annual Report on Form 10-K of Peregrine, for the fiscal year ended April 30, 2017, filed with the SEC on July 14, 2017, and Peregrine’s proxy statement for the 2016 Annual Meeting, filed with the SEC on August 26, 2016. To the extent holdings of such participants in Peregrine’s securities are not reported, or have changed since the amounts described, in the 2016 proxy statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Details concerning the nominees of Peregrine’s Board of Directors for election at the 2017 Annual Meeting will be included in the Proxy Statement. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE COMPANY’S DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders will be able to obtain a copy of the definitive proxy statement and other documents filed by Peregrine free of charge from the SEC’s website, http://www.sec.gov. Peregrine’s stockholders will also be able to obtain, without charge, a copy of the definitive Proxy Statement and other relevant filed documents by directing a request by mail to Peregrine, Corporate Secretary’s Office, 14282 Franklin Avenue, Tustin, CA 92780, by calling Peregrine’s proxy solicitor, MacKenzie Partners, Inc., toll-free at [phone], or from Peregrine’s website at http://www.peregrineinc.com.

nEOL5SMTDG

© Thomson Reuters 2017. All rights reserved.